Faes Farma
Spain - Leioa
BiotechnologyFocus: Small Molecules
Faes Farma is a life sciences company focused on Small Molecules.
Dermatology
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
0
Pipeline & Clinical Trials
[14C]-bilastine
HealthyClinical Trials (1)
NCT00572611Human Mass Balance Study With Bilastine
Phase 1bilastine
HealthyClinical Trials (1)
NCT00419783A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
Phase 1Bilastine
HealthyClinical Trials (1)
NCT01124123Oral Bioavailability of Bilastine
Phase 1Bilastine
Allergic RhinoconjunctivitisClinical Trials (1)
NCT01081574Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
Phase 1/2Bilastine
Seasonal Allergic RhinitisClinical Trials (1)
NCT00574210PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
Phase 2Bilastine
Seasonal Allergic RhinitisClinical Trials (1)
NCT00420082A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
Phase 2BAT + Calcifediol
SARS-CoV 2Clinical Trials (1)
NCT04366908Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Phase 2Bilastine 0.2%
Allergic ConjunctivitisClinical Trials (1)
NCT03231969A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Phase 2Bilastine
Seasonal Allergic RhinitisClinical Trials (1)
NCT00574379Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Phase 2Calcifediol 75mcg
Vitamin D DeficiencyClinical Trials (1)
NCT04735926Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Phase 2/3Bilastine
Cold Contact UrticariaClinical Trials (1)
NCT01271075Bilastine Updosing - Characterization of Underlying Mechanisms
Phase 2/3Bilastine
Allergic ConjunctivitisClinical Trials (1)
NCT04810390Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Phase 3Bilastine
Seasonal Allergic RhinitisClinical Trials (1)
NCT01108783A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
Phase 3Hemorrane plus
Haemorrhoids Without ComplicationClinical Trials (1)
NCT05788497Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids
Phase 3bilastine
Seasonal Allergic RhinitisClinical Trials (1)
NCT00504933Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
Phase 3Mesalazine
Colitis, UlcerativeClinical Trials (1)
NCT06176560Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
Phase 3Bilastine
UrticariaClinical Trials (1)
NCT00421109Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Phase 3Bilastine
Perennial Allergic RhinitisClinical Trials (1)
NCT01127620Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
Phase 3Bilastine Ophthalmic Solution 0.6%
Allergic ConjunctivitisClinical Trials (1)
NCT03479307A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 19 clinical trials
Top TAs: Dermatology, Infectious Diseases, Respiratory
Publications: 25 in PubMed
Therapeutic Area Focus
Marketed
Pipeline